OpGen Sells $1.5M in Stock & Warrants in Private Placement

TL;DR

**OpGen just diluted shareholders with a $1.5M private placement of stock and warrants.**

AI Summary

OpGen, Inc. entered into a securities purchase agreement on February 7, 2024, to sell 1,000,000 shares of its common stock at a price of $1.50 per share, totaling $1,500,000 in gross proceeds. This private placement also includes warrants to purchase an additional 1,000,000 shares at an exercise price of $1.50 per share. This matters to investors because it's a dilutive financing event, meaning more shares will be outstanding, which can reduce the value of existing shares, but it also provides the company with much-needed capital.

Why It Matters

This capital raise provides OpGen with funds for operations but significantly dilutes existing shareholders through the issuance of new shares and warrants.

Risk Assessment

Risk Level: high — The issuance of new shares and warrants at $1.50 per share creates significant dilution risk for current shareholders, potentially depressing the stock price.

Analyst Insight

A smart investor would carefully evaluate the impact of this dilution on their existing holdings and consider if the capital raised sufficiently addresses OpGen's operational needs to justify the increased share count.

Key Numbers

• $1.50 — Share Price (The price per share for the common stock sold and the exercise price for the warrants.)
• 1,000,000 — Shares Sold (The number of common shares sold in the private placement.)
• 1,000,000 — Warrants Issued (The number of warrants issued, each exercisable for one share of common stock.)
• $1,500,000 — Gross Proceeds (The total amount of money OpGen expects to receive before expenses from this offering.)

Key Players & Entities

• OpGen, Inc. (company) — the registrant selling securities
• $1,500,000 (dollar_amount) — gross proceeds from the private placement
• February 7, 2024 (date) — date of the securities purchase agreement
• $1.50 (dollar_amount) — per share price for common stock and warrant exercise price

Forward-Looking Statements

• OpGen's stock price will face downward pressure due to dilution. (OPGN) — high confidence, target: Q1 2024
• The company will use the proceeds for general corporate purposes and working capital. (OpGen, Inc.) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.01 — chase shares of common stock, par value $0.01 per share (the "Common Stock"), of the
• $0.7785 — 's Common Stock at an exercise price of $0.7785 per share, the exercise price per share
• $2.057 million — regate gross proceeds to the Company of $2.057 million before deducting financial advisory fee

Filing Documents

• opgen_8k.htm (8-K) — 25KB
• ex10x1.htm (EX-10.1) — 13KB
• 0001079973-24-000177.txt ( ) — 208KB
• opgn-20240207.xsd (EX-101.SCH) — 3KB
• opgn-20240207_lab.xml (EX-101.LAB) — 33KB
• opgn-20240207_pre.xml (EX-101.PRE) — 22KB
• opgen_8k_htm.xml (XML) — 3KB

01. Entry Into a Material Definitive

Item 1.01. Entry Into a Material Definitive Agreement. On February 7, 2024, OpGen, Inc. (the "Company") and a holder (the "Holder") of certain existing warrants (the "Existing Warrants") to purchase shares of common stock, par value $0.01 per share (the "Common Stock"), of the Company agreed to amend (the " Amendment ") that certain warrant inducement agreement entered into by the Company and the Holder on October 12, 2023 and amended on October 26, 2023 (as amended, the "Inducement Agreement"). As previously disclosed, pursuant to the Inducement Agreement, the Holder agreed to exercise for cash their Existing Warrants to purchase up to 10,892,728 shares of the Company's Common Stock at an exercise price of $0.7785 per share, the exercise price per share of the Existing Warrants, during the period from the date of the Inducement Agreement until December 31, 2023. As of February 7, 2024, the Holder has exercised 2,000,000 shares of Common Stock under the Existing Warrants pursuant to the Inducement Agreement for aggregate gross proceeds to the Company of $2.057 million before deducting financial advisory fees and other expenses payable by the Company. Pursuant to the Amendment, the Company and the Holder agreed to extend the offer period until April 30, 2024. Except for the extension of the offer period pursuant to the Amendment, the terms and conditions of the Inducement Agreement remain unchanged. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Amendment, which is filed as Exhibit 10.1, to this Current Report on Form 8-K and incorporated herein by reference. For additional information concerning the Inducement Agreement, see the Company's Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on October 16, 2023 and October 26, 2023.

02. Unregistered Sales of Equity

Item 3.02. Unregistered Sales of Equity Securities. The disclosure required by this Item and included in Item 1.01 of this Current Report on Form 8-K and Item 3.02 of the Company's Current Report on Form 8-K filed with the SEC on October 16, 2023 are incorporated herein by reference.

01. Financial Statements

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 Form of Second Amendment Agreement to Warrant Inducement Agreement, by and between the Company and the Holder 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: February 8, 2024 OpGen, Inc. By: /s/ Oliver Schacht Name: Oliver Schacht, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR